The purpose of this study is to evaluate the effectiveness and safety of an investigational drug called CVL-751 (also known as tavapadon) as a possible treatment for Parkinson's disease. Tavapadon works by targeting the dopamine system in the brain. Participants will be randomly assigned to receive either the study drug or placebo (inactive substance); they will have a 67% (2 in 3) chance of receiving CVL-751 and a 33% (1 in 3) chance of receiving placebo. The study is divided into 3 time periods: a 4-week screening/baseline period, a 27-week treatment period, and a 4-week post-treatment follow-up period. During each study period, participants will have one or more visits with their study doctor.
Full Title
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON S DISEASE